Supernus Pharmaceuticals, Inc. (SUPN)

52.03 +0.58 (+1.13%) USD  |  NASDAQ  |  May 07, 12:18
More

Supernus Pharmaceuticals SG&A Expense (TTM) : 395.62M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Biogen, Inc. 2.468B
Corcept Therapeutics, Inc. 503.42M
BridgeBio Pharma, Inc. 531.22M
Cytokinetics, Inc. 226.90M
Oncotelic Therapeutics, Inc. 3.182M